000177230 001__ 177230
000177230 005__ 20240229133734.0
000177230 0247_ $$2doi$$a10.1016/j.ijrobp.2021.07.829
000177230 0247_ $$2pmid$$apmid:34701007
000177230 0247_ $$2ISSN$$a0360-3016
000177230 0247_ $$2ISSN$$a1879-355X
000177230 037__ $$aDKFZ-2021-02364
000177230 041__ $$aEnglish
000177230 082__ $$a610
000177230 1001_ $$0P:(DE-He78)dc4247d1e899d0fd333732064f422a0f$$aLiew, Hans$$b0$$eFirst author$$udkfz
000177230 245__ $$aCombined DNA Damage Repair Inhibition and Ion Beam Therapy: Development, Benchmark and Clinical Implications of a Mechanistic Biological Model.
000177230 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000177230 3367_ $$2DRIVER$$aarticle
000177230 3367_ $$2DataCite$$aOutput Types/Journal article
000177230 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1650981245_16147$$xOther
000177230 3367_ $$2BibTeX$$aARTICLE
000177230 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177230 3367_ $$00$$2EndNote$$aJournal Article
000177230 500__ $$a#EA:E050# Abstract
000177230 520__ $$aCellular radiosensitivity is tightly linked to DNA damage repair (DDR) capability. In a clinical context, inhibition of key DDR enzymes within tumor results in improved tumor control after radiotherapy and many preclinical and clinical trials of radiosensitizing drugs targeting DDR enzymes have been recently conducted or launched. Concurrently, interest in ion beam therapy continues to grow globally and its high precision may provide ideal treatment attributes in combination with tumor radiosensitizers. However, most studies of tumor radiosensitization based on DDR inhibition have been or are conducted using prevalent photon beams. Here, a mechanistic model of biological radiation response is presented to accurately translate findings in DDR inhibition studies to the case of charged particle radiation.The mechanistic 'UNIfied and VErsatile bio-response Engine' (UNIVERSE) and its model of radiosensitization by DDR inhibition is extended to charged particles by implementing the heterogeneous dose distributions of protons and helium ions utilizing GPU computation. Predictions for monoenergetic and mixed fields over clinically relevant dose and LET range are compared to cell survival data from the literature and own dedicated experiments, including different cell lines and DDR inhibited variants. Our own experimental data represents the first comprehensive measurement of cell survival of repair competent and deficient cell lines in a helium spread-out bragg peak. Ultimately, the predictions of UNIVERSE are considered in a concrete clinical situation based on patient plan recalculations.UNIVERSE is able to precisely predict cell survival of DDR competent and deficient cell lines in clinically relevant settings of ion beam therapy based only on up to 3 parameters derived solely from conventional photon data. With increasing LET the effect of DDR deficiency reduces. This results in a diminished RBE of ion beam radiation for DDR deficient cells in comparison to DDR proficient cells.The capabilities of UNIVERSE could lead towards more personalized and 'biological' planning in charged particle therapy, that could be guided by bio-marker based imaging in the future. By increasing the coverage of a tumor with high-LET using modifications of the treatment planning optimizer or advanced irradiation techniques, one could exploit the reduced impact of DDR inhibition at high LET to reduce the adverse effects of heterogeneous tumor radiosensitivity. UNIVERSE could also aid the appraisal of clinical viability of combined administration of radiosensitizing drugs and charged particle therapy and the identification of patients with known DDR inhibition which might not benefit from ion beam therapy, facilitating the management of limited capacities at therapy centers.
000177230 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000177230 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177230 7001_ $$0P:(DE-He78)df14a88d357c289b53f2561141bd9ca9$$aMeister, Sarah$$b1$$udkfz
000177230 7001_ $$0P:(DE-HGF)0$$aMein, S.$$b2
000177230 7001_ $$0P:(DE-He78)32565894b8bfbe22e80198849cca18a2$$aKopp, B.$$b3$$udkfz
000177230 7001_ $$0P:(DE-He78)360c5bc2b71a849e35aca747c041dda7$$aAbdollahi, A.$$b4$$udkfz
000177230 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, J.$$b5$$udkfz
000177230 7001_ $$0P:(DE-He78)e24b607ded082a3089a1f6bf326a7a8e$$aDokic, I.$$b6$$udkfz
000177230 7001_ $$aMairani, A.$$b7
000177230 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2021.07.829$$gVol. 111, no. 3S, p. e247 - e248$$n3S$$pe247 - e248$$tInternational journal of radiation oncology, biology, physics$$v111$$x0360-3016$$y2021
000177230 909CO $$ooai:inrepo02.dkfz.de:177230$$pVDB
000177230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)dc4247d1e899d0fd333732064f422a0f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)df14a88d357c289b53f2561141bd9ca9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000177230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32565894b8bfbe22e80198849cca18a2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000177230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)360c5bc2b71a849e35aca747c041dda7$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000177230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000177230 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e24b607ded082a3089a1f6bf326a7a8e$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000177230 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000177230 9141_ $$y2021
000177230 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-27$$wger
000177230 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2019$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-27
000177230 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J RADIAT ONCOL : 2019$$d2021-01-27
000177230 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000177230 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000177230 9201_ $$0I:(DE-He78)E210-20160331$$kE210$$lE210 Translationale Radioonkologie$$x2
000177230 980__ $$ajournal
000177230 980__ $$aVDB
000177230 980__ $$aI:(DE-He78)E050-20160331
000177230 980__ $$aI:(DE-He78)HD01-20160331
000177230 980__ $$aI:(DE-He78)E210-20160331
000177230 980__ $$aUNRESTRICTED